ClinicalTrials.gg
CompletedNCT03102606Protective-1Updated Aug 29, 2024Results posted

Plinabulin vs. Pegfilgrastim in Patients With Solid Tumors Receiving Docetaxel Myelosuppressive Chemotherapy Phase 3

A Phase 3 interventional study of Plinabulin and Pegfilgrastim in Chemotherapy-induced Neutropenia, sponsored by BeyondSpring Pharmaceuticals Inc.. Completed at 18 sites in 4 countries. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2024-08-29.

Sponsored by BeyondSpring Pharmaceuticals Inc. · Phase 3, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 3
Study type
Interventional
Enrollment
105
Allocation
Randomized
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-16

Among 42 studies in Neutropenia with a site in China — 11 open to participants now, 12 under way, 1 of them phase 3. Neutropenia · China.

Enrollment
20th of 36
105 · median 119
Started
2018
with 4 others
Phase 3
7 of 42
none open now
Registered
17th of 42
by date
Lead sponsor
4 of 42
BeyondSpring Pharmaceuticals Inc.

Among the 42 studies in Neutropenia with a site in China, this one is the 20th largest by enrollment of the 36 interventional ones that give a count, is one of 5 that started in 2018, is one of 7 in phase 3, and was the 17th registered.

Neutropenia

316 studies on the registry are indexed under Neutropenia; 42 are open to participants now.

Browse Neutropenia studies →

Open to participants now

11 of the 42 studies in Neutropenia with a site in China are open now. Recruiting first, the newest first:

6 more — sign in →

All 11 open studies →

A study can be open while its sites in China have not opened yet or have stopped. Only those recruiting at a site in China →

Who these studies take

Of the 24 Neutropenia studies recruiting now, 12 (50%) set no upper age limit and 12 (50%) stop at 75 or younger; 11 take children under 18; 1 takes healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 42 studies in Neutropenia with a site in China, or all of them as a file.
02

Study summary

To assess Duration of Severe Neutropenia (DSN) in treatment Cycle 1 in patients with advanced or metastatic breast cancer, who have failed >/= 1 but \< 5 prior lines of chemotherapy; locally advanced or metastatic non small cell lung cancer (NSCLC) after platinum therapy failure; or hormone refractory (androgen independent) metastatic prostate cancer treated with docetaxel (75 mg/m2) + plinabulin (40 mg) versus docetaxel (75 mg/m2) + pegfilgrastim (6 mg). Neutrophils count will be assessed at baseline; Pre dose during Cycle 1, Day 1, 2, 6, 7, 8, 9, 10, 15.

*Study is officially closed on 08 Feb 2021*

Read the detailed description

Arm 1: Docetaxel (75 mg/m2) + pegfilgrastim (6 mg) + placebo matching plinabulin

Arm 2: Docetaxel (75 mg/m2) + plinabulin (40 mg) + placebo matching pegfilgrastim

03

Conditions studied

  • Chemotherapy-induced Neutropenia

Browse trials for

Keywords

  • Plinabulin
  • Pegfilgrastim
  • Duration of Severe Neutropenia
  • Bone Pain
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. At least ≥ 18 years of age (male or female) at the time of signing the form.
  2. performance status of 0 to 1.
  3. Patients with:

    Phase 2 only:

    • Advanced or NSCLC failing platinum-based therapy

    Phase 3 only:

    • Advanced or metastatic breast cancer, who have failed \< 5 (Note that study treatment may be the first chemotherapy treatment for advanced or metastatic cancer)
    • locally advanced or metastatic NSCLC after platinum therapy failure
    • HRPC (Note that study treatment may be the first chemotherapy treatment)
  4. Pathology confirmation of cancer is required.
  5. Patients with ≥ 1 of the following risk factors, at the initiation of docetaxel chemotherapy, that would require neutropenia prophylaxis per National Comprehensive Cancer Network (NCCN) guidelines (version 2, 2016):

    • Prior chemotherapy or radiation treatment
    • Bone marrow involvement by tumor
    • Surgery and/or open wounds within 4 weeks of first administration of study drug
    • Age > 65 years of age and receiving full chemotherapy dose intensity
  6. of 3 months or more.
  7. The following laboratory results assessed within 14 days prior to study drug administration:

    • >/= 9 g/dL independent of transfusion or growth factor support
    • (ANC) >/= 1.5 x 10**9/L independent of growth factor support
    • Serum total \</= 1.5 times the upper limit normal (), unless the patient has a diagnosis of Gilbert's disease, in which case direct bilirubin \</= 1.5 times ULN of the direct bilirubin.
    • (AST) and alanine aminotransferase (ALT) \</= 2.5 x ULN (\</= 1.5 x ULN if alkaline phosphatase is > 2.5 x ULN)
    • Serum creatinine \</= 1.5 x ULN

    Note: Results are from the central laboratory. Local laboratory results may be accepted on a case by case basis after discussion with the Medical Monitor, however in this case central laboratories must also be taken within the screening time window.

  8. (PT)/International Normalized Ratio (INR) ≤ 1.5 × upper limit of normal (ULN), activated partial thromboplastin time (PTT) ≤ 1.5 × ULN, based on central laboratory results.
  9. Female subjects of have a negative pregnancy test at screening. Females of childbearing potential are defined as sexually mature women without prior hysterectomy or who have had any evidence of menses in the past 12 months. However, women who have been amenorrhoeic for 12 or more months are still considered to be of childbearing potential if the amenorrhea is possibly due to prior chemotherapy, anti-estrogens, or ovarian suppression.

    • Women of childbearing potential (i.e., menstruating women) must have a negative urine pregnancy test (positive urine tests are to be confirmed by serum test) documented within the 24-hour period prior to the first dose of study drug.
    • Sexually active women of childbearing potential enrolled in the study must agree to use two forms of accepted methods of during the course of the study and for 3 months after their last dose of study drug. Effective birth control includes (a) intrauterine device (IUD) plus one barrier method; (b) on stable doses of hormonal contraception for at least 3 months (e.g., oral, injectable, implant, transdermal) plus one barrier method; (c) 2 barrier methods. Effective barrier methods are male or female condoms, diaphragms, and spermicides (creams or gels that contain a chemical to kill sperm); or (d) a vasectomized partner.
    • For male patients who are sexually active and who are partners of premenopausal women: agreement to use two forms of contraception during the treatment period and for at least 3 months after the last dose of study drug.

Exclusion criteria

Exclusion Criteria:

  1. History of myelogenous leukemia, myelodysplastic syndrome or concomitant sickle cell disease.
  2. Received chemotherapy within 4 weeks prior to the first dose of study drug.
  3. Received prior docetaxel treatment, except adjuvant docetaxel given > 1 year prior to first dose of study drug
  4. Phase 3 only: Received >/= 5 lines of cytotoxic chemotherapy for advanced or breast cancer ( chemotherapy will count as one , and any hormonal or biological, non conjugate therapy [e.g., trastuzumab] will not count as a line of therapy).
  5. Current use of strong cytochrome P450 (CYP) 3A4 inhibitors, within 3 days of the first administration of study drug, and 7 days after treatment with taxanes OR requires use of strong inhibitors
  6. Received an agent or tumor vaccine within 2 weeks before the first dose of study drug; patients must have recovered from toxicity of prior treatment and have no > Grade 1 (v4.03) treatment emergent AEs.
  7. Receiving any concurrent anticancer therapies (except continued hormonal treatment).
  8. Received a prior bone marrow or stem cell transplant.
  9. Has a co-existing active infection or received systemic anti-infective treatment within 72 hours before the first dose of study drug.
  10. Prior radiation therapy within the 4 weeks before the first dose of study drug.
  11. Prior use of pegfilgrastim or filgrastim within 4 weeks before the first dose of study drug.
  12. Presence of any serious or uncontrolled illness including, but not limited to: uncontrolled diabetes, ongoing or active infection, symptomatic congestive heart failure, unstable angina pectoris, uncontrolled cardiac arrhythmia, uncontrolled arterial thrombosis, symptomatic pulmonary embolism, or psychiatric illness that would limit compliance with study requirements, or any other conditions that would preclude the patient from study treatment as per the discretion of the Investigator.
  13. Significant cardiovascular history:

    • History of myocardial infarction or ischemic heart disease within 1 year (within a window of up to 18 days less than 1 year) before first study drug administration;
    • Uncontrolled arrhythmia;
    • History of congenital ;
    • (ECG) findings consistent with active ischemic heart disease;
    • Class III or IV cardiac disease;
    • Uncontrolled hypertension: blood pressure consistently >150 mm Hg systolic and > 100 mm Hg diastolic in spite of antihypertensive medication.
  14. History of hemorrhagic diarrhea, inflammatory bowel disease, or active uncontrolled peptic ulcer disease. (Concomitant therapy with ranitidine or its equivalent and/or omeprazole or its equivalent is acceptable). History of ileus or other significant gastrointestinal disorder known to predispose to ileus or chronic bowel hypomotility.
  15. Any other requiring active therapy.
  16. Known (HIV) seropositivity.
  17. Active virus (HBV) infection which requires antiviral treatment. Patients with detectable Hepatitis B surface Antigen (HBsAg) may be eligible provided the patient has a negative viral load. Patients with a positive HBsAg must have a negative viral load before each chemotherapy administration. Hepatitis B surface antibody (anti HBs) without detectable HBsAg does NOT exclude patients from the study. infection (Hepatitis C antibody reactive) which requires treatment also excludes patients from the study.
  18. Female subject who is pregnant or lactating.
  19. Unwilling or unable to comply with procedures required in this protocol
Terms in these criteria, in plain language(24)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

ECOG performance status

A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.

0
Fully active, no restrictions.
1
Limited in strenuous activity, but walking and able to do light work, such as housework or office work.
2
Walking and able to look after yourself, but unable to work; up and about more than half of waking hours.
3
Able to look after yourself only in part; in bed or a chair more than half of waking hours.
4
Unable to look after yourself at all; in bed or a chair all day.

Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.

Metastases

Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.

Line of therapy

A line of therapy is one course of treatment, which may combine several drugs. First-line is the first course given; second-line follows when that stops working or is not tolerated.

“Two prior lines” means two courses that count separately under the study’s rules — not simply two drugs. Ask the study team if you are unsure how yours are counted.

Life expectancy

The study doctor’s estimate of how long someone is likely to live. Criteria use it so that people can stay in the study long enough for it to answer its question.

Hemoglobin (Hb)

The protein in red blood cells that carries oxygen. A low level is anemia, which can cause tiredness and breathlessness. Measured in g/dL or g/L (9 g/dL is 90 g/L).

Absolute neutrophil count (ANC)

The number of neutrophils, white blood cells that help fight infection, in a given amount of blood. Too few raises the risk of infection.

It is a count, not a percentage of the white cells. Limits are written in units that mean the same: ≥ 1.5 × 10⁹/L is ≥ 1,500 per mm³ (µL). Each lab has its own reference range.

Bilirubin

A yellow substance made when red blood cells are broken down, which the liver clears. A high level can mean a problem with the liver or the bile ducts.

Criteria often allow more for people with Gilbert’s syndrome, a harmless inherited condition that raises bilirubin.

ULN (upper limit of normal)

The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.

“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.

ALT and AST (liver enzymes)

Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.

Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.

INR, PT and aPTT (clotting tests)

Blood tests of how long blood takes to clot. The INR is the prothrombin time (PT) put on a common scale; about 1 is usual for someone not taking a blood thinner.

Criteria often make an exception for people on a blood thinner such as warfarin, whose INR is raised on purpose.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Adjuvant and neoadjuvant

Neoadjuvant treatment is given before the main treatment (usually surgery), often to shrink a tumor. Adjuvant treatment is given after it, to lower the chance of the cancer coming back.

CYP3A (CYP3A4) inhibitors and inducers

CYP3A is a group of enzymes, mainly CYP3A4, in the liver and gut that break down many medicines. Some medicines, supplements and foods (grapefruit, St John’s wort) slow them down or speed them up, which changes how much of a study drug stays in the body.

Studies list them so they can be avoided or switched; bring a list of everything you take, including supplements.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

CTCAE grade

The US National Cancer Institute’s scale of how severe an adverse event is — any unwanted medical event during a study, such as a symptom, an illness or an abnormal test result, whether or not a treatment caused it. Whether it did is judged separately.

1
Mild.
2
Moderate.
3
Severe.
4
Life-threatening.
5
Death due to the event.

“Side effects of earlier treatment resolved to grade 1 or less” means they have settled to mild or gone.

QT and QTc

On an ECG, the QT interval is the time the heart’s lower chambers take to activate electrically and recover in each beat. QTc is that time adjusted for heart rate (QTcF by Fridericia’s formula, QTcB by Bazett’s). Some medicines lengthen it, and a long QTc can raise the risk of a dangerous heart rhythm.

The study may name a correction formula and a limit in milliseconds, often around 450–480.

ECG (electrocardiogram)

A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.

NYHA class (heart failure)

The New York Heart Association’s four classes of how much heart failure limits physical activity.

I
No limits: ordinary activity causes no undue tiredness or breathlessness.
II
Slight limits: comfortable at rest, ordinary activity causes symptoms.
III
Marked limits: comfortable at rest, less than ordinary activity causes symptoms.
IV
Symptoms even at rest; any activity makes them worse.

Studies set their own limit — many outside heart failure leave out class III–IV, while heart failure studies may ask for a particular class. Check the class this study names.

Cancer (malignancy)

Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.

Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

Hepatitis B tests

Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.

Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.

Hepatitis C tests

Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.

After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.

05

Study design

Phase
Phase 3
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Triple (Participant, Care provider, Investigator)
Enrollment
105 participants (actual)

Study arms

  • Active comparator
    Docetaxel (75 mg/m2) + pegfilgrastim (6 mg) + placebo matching plinabulin

    Arm 1

    Drug: Pegfilgrastim · Other: D5W Placebo

  • Experimental
    Docetaxel (75 mg/m2) + plinabulin (40 mg) + placebo matching pegfilgrastim

    Arm 2

    Drug: Plinabulin · Other: Saline Placebo

Interventions

  • Plinabulin (BPI-2358) is a synthetic, low molecular weight, new chemical entity that belongs to the diketopiperazine class of compounds. Plinabulin is intended for intravenous (IV) infusion and is diluted in D5W and administered for 30 minutes (± 5 minutes).

    Also known as: BPI-2358, NPI-2358

  • PEGFILGRASTIM is a long-acting granulocyte colony-stimulating factor that stimulates the growth of neutrophils, to reduce the incidence of fever and infection in patients with certain types of cancer who are receiving chemotherapy that affects the bone marrow.

    Also known as: Neulasta, G-CSF

  • OtherSaline Placebo

    Placebo Syringe 0.6 ml Saline to match the 0.6 ml pegfilgrastim administration

  • OtherD5W Placebo

    Placebo 250 ml D5W to match the administration of plinabulin diluted in 250 ml D5W

06

What researchers measure

Primary outcomes

  1. Duration of Severe Neutropenia (DSN)

    Duration of severe neutropenia (ANC \< 0.5 × 109/L)

    Time frame: 21 Days

Secondary outcomes

  1. Change in Estimated Mean Bone Pain Score

    Change in estimated mean bone pain score from pre-dose Day 1 through Day 8. The bone pain scale assessment was based on the validated Wong-Baker Faces® Pain Rating Scale. The pain scale range is from 0 to 10. The severity of pain marked on a scale is from 0 ('no hurt') to 10 ('hurt worst').

    Time frame: Day 1 through 8 in Cycle 1 (each cycle is 21 days)

  2. Change in Patients With at Least 30% Platelet Count From Baseline in Cycle 1

    Patients with platelet count at least 30% change from baseline at any time during Cycle 1

    Time frame: Anytime during Cycle 1 (each cycle is 21 days)

  3. Proportion of Patients With Neutrophil-to-lymphocyte Ratio (NLR) > 5

    Proportion of patients with neutrophil-to-lymphocyte ratio (NLR) \> 5 from Day 1 through Day 15

    Time frame: 15 Days

  4. Proportion of Patients With Thrombocytopenia

    Proportion of patients with thrombocytopenia (all grade) during 4 cycles

    Time frame: 84 days

  5. Infections

    Incidence of infections in cycles 1 to 4

    Time frame: 84 Days

  6. Antibiotic Use

    Incidence of antibiotic use

    Time frame: 21 Days

  7. Sepsis

    To assess the incidence of sepsis

    Time frame: 84 Days

07

Results

Posted Aug 29, 2024

Participant flow

Participant flow — Overall Study
MilestoneDocetaxel (75 mg/m2) + Pegfilgrastim (6 mg) + Placebo Matching PlinabulinDocetaxel (75 mg/m2) + Plinabulin (40 mg) + Placebo Matching Pegfilgrastim
Started5352
Completed3945
Not completed147

Outcome measures

PrimaryDuration of Severe Neutropenia (DSN)

Duration of severe neutropenia (ANC \< 0.5 × 109/L)

Time frame:
21 Days
Reported as:
Mean · Days
Duration of Severe Neutropenia (DSN)
DaysDocetaxel (75 mg/m2) + Pegfilgrastim (6 mg) + Placebo Matching PlinabulinDocetaxel (75 mg/m2) + Plinabulin (40 mg) + Placebo Matching Pegfilgrastim
Duration of Severe Neutropenia (DSN)0.246 (0.205 to 0.287)0.770 (0.682 to 0.857)
SecondaryChange in Estimated Mean Bone Pain Score

Change in estimated mean bone pain score from pre-dose Day 1 through Day 8. The bone pain scale assessment was based on the validated Wong-Baker Faces® Pain Rating Scale. The pain scale range is from 0 to 10. The severity of pain marked on a scale is from 0 ('no hurt') to 10 ('hurt worst').

Time frame:
Day 1 through 8 in Cycle 1 (each cycle is 21 days)
Reported as:
Least squares mean · Wong-Baker FACES Pain Scale (range:0-10)
Change in Estimated Mean Bone Pain Score
Wong-Baker FACES Pain Scale (range:0-10)Docetaxel (75 mg/m2) + Pegfilgrastim (6 mg) + Placebo Matching PlinabulinDocetaxel (75 mg/m2) + Plinabulin (40 mg) + Placebo Matching Pegfilgrastim
Change in Estimated Mean Bone Pain Score2.35 ± 0.1781.69 ± 0.179
SecondaryChange in Patients With at Least 30% Platelet Count From Baseline in Cycle 1

Patients with platelet count at least 30% change from baseline at any time during Cycle 1

Time frame:
Anytime during Cycle 1 (each cycle is 21 days)
Reported as:
Count of participants · Participants
Change in Patients With at Least 30% Platelet Count From Baseline in Cycle 1
ParticipantsDocetaxel (75 mg/m2) + Pegfilgrastim (6 mg) + Placebo Matching PlinabulinDocetaxel (75 mg/m2) + Plinabulin (40 mg) + Placebo Matching Pegfilgrastim
Change in Patients With at Least 30% Platelet Count From Baseline in Cycle 14123
SecondaryProportion of Patients With Neutrophil-to-lymphocyte Ratio (NLR) > 5

Proportion of patients with neutrophil-to-lymphocyte ratio (NLR) \> 5 from Day 1 through Day 15

Time frame:
15 Days
Reported as:
Count of participants · Participants
Proportion of Patients With Neutrophil-to-lymphocyte Ratio (NLR) > 5
ParticipantsDocetaxel (75 mg/m2) + Pegfilgrastim (6 mg) + Placebo Matching PlinabulinDocetaxel (75 mg/m2) + Plinabulin (40 mg) + Placebo Matching Pegfilgrastim
Proportion of Patients With Neutrophil-to-lymphocyte Ratio (NLR) > 5242
SecondaryProportion of Patients With Thrombocytopenia

Proportion of patients with thrombocytopenia (all grade) during 4 cycles

Time frame:
84 days
Reported as:
Count of participants · Participants
Proportion of Patients With Thrombocytopenia
ParticipantsDocetaxel (75 mg/m2) + Pegfilgrastim (6 mg) + Placebo Matching PlinabulinDocetaxel (75 mg/m2) + Plinabulin (40 mg) + Placebo Matching Pegfilgrastim
Proportion of Patients With Thrombocytopenia1910
SecondaryInfections

Incidence of infections in cycles 1 to 4

Time frame:
84 Days
Reported as:
Count of participants · Participants
Infections
ParticipantsDocetaxel (75 mg/m2) + Pegfilgrastim (6 mg) + Placebo Matching PlinabulinDocetaxel (75 mg/m2) + Plinabulin (40 mg) + Placebo Matching Pegfilgrastim
Infections84
SecondaryAntibiotic Use

Incidence of antibiotic use

Time frame:
21 Days
Reported as:
Count of participants · Participants
Antibiotic Use
ParticipantsDocetaxel (75 mg/m2) + Pegfilgrastim (6 mg) + Placebo Matching PlinabulinDocetaxel (75 mg/m2) + Plinabulin (40 mg) + Placebo Matching Pegfilgrastim
Antibiotic Use78
SecondarySepsis

To assess the incidence of sepsis

Time frame:
84 Days
Reported as:
Count of participants · Participants
Sepsis
ParticipantsDocetaxel (75 mg/m2) + Pegfilgrastim (6 mg) + Placebo Matching PlinabulinDocetaxel (75 mg/m2) + Plinabulin (40 mg) + Placebo Matching Pegfilgrastim
Sepsis00

Adverse events

Collected over 6 months. Non-serious events are listed at a 5% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
Docetaxel (75 mg/m2) + Pegfilgrastim (6 mg) + Placebo Matching Plinabulin1/53 (1.9%)6/53 (11.3%)49/53 (92.5%)
Docetaxel (75 mg/m2) + Plinabulin (40 mg) + Placebo Matching Pegfilgrastim2/52 (3.8%)8/52 (15.4%)51/52 (98.1%)
Most frequent serious events
Showing 10 of 13
Most frequent serious events
EventDocetaxel (75 mg/m2) + Pegfilgrastim (6 mg) + Placebo Matching PlinabulinDocetaxel (75 mg/m2) + Plinabulin (40 mg) + Placebo Matching Pegfilgrastim
Lung infectionInfections and infestations2/21/52
Febrile NeutropeniaBlood and lymphatic system disorders1/531/52
AnemiaBlood and lymphatic system disorders0/531/52
VomitingGastrointestinal disorders0/531/52
Aspartate aminotransferase increasedInvestigations0/531/52
Neutrophil count decreasedInvestigations0/531/52
White blood cell count decreasedInvestigations0/531/52
Renal failureRenal and urinary disorders0/531/52
Pulmonary embolismRespiratory, thoracic and mediastinal disorders0/531/52
Status asthmaticusRespiratory, thoracic and mediastinal disorders0/531/52
Most frequent other events
Showing 10 of 32
Most frequent other events
EventDocetaxel (75 mg/m2) + Pegfilgrastim (6 mg) + Placebo Matching PlinabulinDocetaxel (75 mg/m2) + Plinabulin (40 mg) + Placebo Matching Pegfilgrastim
Neutrophil count decreasedInvestigations10/5323/52
White blood cell count decreasedInvestigations10/5321/52
Bone painMusculoskeletal and connective tissue disorders15/5318/52
AnemiaBlood and lymphatic system disorders13/5317/52
AlopeciaSkin and subcutaneous tissue disorders17/5317/52
HyperglycemiaMetabolism and nutrition disorders13/538/52
NeutropeniaBlood and lymphatic system disorders7/5312/52
DiarrheaGastrointestinal disorders5/5311/52
LeukopeniaBlood and lymphatic system disorders7/5310/52
Decreased appetiteMetabolism and nutrition disorders5/5310/52

Baseline characteristics

Age, Categorical
Age, Categorical(Participants)Docetaxel (75 mg/m2) + Pegfilgrastim (6 mg) + Placebo Matching PlinabulinDocetaxel (75 mg/m2) + Plinabulin (40 mg) + Placebo Matching PegfilgrastimTotal
<=18 years000
Between 18 and 65 years344074
>=65 years191231
Age, Continuous
Age, Continuous(years)Docetaxel (75 mg/m2) + Pegfilgrastim (6 mg) + Placebo Matching PlinabulinDocetaxel (75 mg/m2) + Plinabulin (40 mg) + Placebo Matching PegfilgrastimTotal
Mean58.9 ± 10.8557.0 ± 10.7958.0 ± 10.81
Sex: Female, Male
Sex: Female, Male(Participants)Docetaxel (75 mg/m2) + Pegfilgrastim (6 mg) + Placebo Matching PlinabulinDocetaxel (75 mg/m2) + Plinabulin (40 mg) + Placebo Matching PegfilgrastimTotal
Female323365
Male211940
Race (NIH/OMB)
Race (NIH/OMB)(Participants)Docetaxel (75 mg/m2) + Pegfilgrastim (6 mg) + Placebo Matching PlinabulinDocetaxel (75 mg/m2) + Plinabulin (40 mg) + Placebo Matching PegfilgrastimTotal
American Indian or Alaska Native000
Asian252550
Native Hawaiian or Other Pacific Islander000
Black or African American000
White282755
More than one race000
Unknown or Not Reported000
08

Study locations

18 sites
  • Stanford University School of Medicine - Cancer Institute
    Stanford, California 94305-5827, United States
  • Hematology/Oncology of the North Shore
    Skokie, Illinois 60076, United States
  • Norton Cancer Institute
    Louisville, Kentucky 40241, United States
  • Heilongjiang Cancer Hospital
    Harbin, Heilongjiang 150000, China
  • Jiangsu Cancer Hospital
    Nanjing, Jiangsu 210000, China
  • Cancer Hospital Chinese Academy of Medical Sciences
    Beijing, China
  • Linyi Cancer Hospital
    Linyi, China
  • Liaoning Cancer Hospital & Institute
    Shenyang, China
  • Henan Cancer Hospital
    Zhengzhou, China
  • State Budgetary Healthcare Institution of Stavropol Territory "Pyatigorsk Interregional Oncology Dispensary"
    Pyatigorsk, Russian Federation
  • SBI of Healthcare "Oncology Dispensary #2" Ministry of Healthcare of Krasnodar Region
    Sochi, 354067, Russian Federation
  • Volgograd Regional Clinical Oncology Dispensary
    Volgograd, 400138, Russian Federation
  • Dnipropetrovsk City Multifunctional Hospital
    Dnepropetrovsk, 49102, Ukraine
  • Prykarpatskiy Regional Oncological Center
    Ivano-Frankivsk, 76000, Ukraine
  • Communal Institution of Kherson Regional Council "Kherson regional oncological dispensary"
    Kherson, 73000, Ukraine
  • Kryvyi Rih Oncology Dispensary
    Kryvyi Rih, Ukraine
  • Lviv State Oncological Regional Treatment and Preventive Center
    Lviv, 79031, Ukraine
  • Municipal Institution "Sumy Regional Clinical Oncology Dispensary"
    Sumy, 40022, Ukraine
09

References and documents

Publications

  • Blayney DW, Mohanlal R, Adamchuk H, Kirtbaya DV, Chen M, Du L, Ogenstad S, Ginn G, Huang L, Zhang Q. Efficacy of Plinabulin vs Pegfilgrastim for Prevention of Docetaxel-Induced Neutropenia in Patients With Solid Tumors: A Randomized Clinical Trial. JAMA Netw Open. 2022 Jan 4;5(1):e2145446. doi: 10.1001/jamanetworkopen.2021.45446. PubMed 35084480 ↗
  • Blayney DW, Zhang Q, Feng J, Zhao Y, Bondarenko I, Vynnychenko I, Kovalenko N, Nair S, Ibrahim E, Udovista DP, Mohanlal R, Ogenstad S, Ette E, Du L, Huang L, Shi YK. Efficacy of Plinabulin vs Pegfilgrastim for Prevention of Chemotherapy-Induced Neutropenia in Adults With Non-Small Cell Lung Cancer: A Phase 2 Randomized Clinical Trial. JAMA Oncol. 2020 Nov 1;6(11):e204429. doi: 10.1001/jamaoncol.2020.4429. Epub 2020 Nov 12. PubMed 32970104 ↗

Study documents

PDFs hosted by the registry, ClinicalTrials.gov.

Individual participant data

Plan to share: No

10

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from May 2018 to primary completion in Dec 2018, 6 months.

Results were first posted in Aug 2024, 5 years 8 months after primary completion.

Of 16 phase 3 interventional studies under Neutropenia, half reached primary completion within 20 months of starting (the median), counting those still running; a quarter within 11 and three quarters within 34. This study's 6 months is below that.

How these figures are worked out, and which studies are left out of them.

Registered
Mar 6, 2017
First posted
Apr 6, 2017
StartActual
May 29, 2018
Primary completionActual
Dec 12, 2018
CompletionActual
Feb 8, 2021
Results first posted
Aug 29, 2024
Last update
Aug 29, 2024
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Aug 29, 2024, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT03102606
Lead sponsor
BeyondSpring Pharmaceuticals Inc.
Collaborators
Covance, ICON plc
Responsible party
Sponsor
First posted
Apr 6, 2017
Start date
May 29, 2018
Primary completion
Dec 12, 2018
Completion
Feb 8, 2021
Results posted
Aug 29, 2024
Last update
Aug 29, 2024

Study contacts

Douglas W. Blayney, MD
principal investigator · Stanford University School of Medicine - Cancer Institute

Oversight

Data monitoring committee
Yes
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Aug 2024. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: NPI 2358

Start the discussion